HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?

HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?

De-escalation is currently taking place in both the surgical and systemic treatment of breast cancer. The introduction of trastuzumab, the first monoclonal antibody against the HER2 receptor, over 20 years ago was a milestone in the treatment of HER2-positive breast cancer and marked the beginning o...

Full description

Bibliographic Details
Main Authors: Nikolas Tauber, Christoph Cirkel, Anna Claussen, Franziska Fick, Emmanuel Kontomanolis, Natalia Krawczyk, Achim Rody, Maggie Banys-Paluchowski
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
HER2-positive
breast cancer
systemic de-escalation
chemo-free therapy
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/16/6/1121

Internet

https://www.mdpi.com/2072-6694/16/6/1121

Similar Items